2 results match your criteria: "Lazzaro Spallanzani National Infectious Disease Institute[Affiliation]"
Cumulative incidence of solid and hematological De novo malignancy after liver transplantation in a multicentre cohort.
Ann Hepatol
February 2022
Gastroenterology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. Electronic address:
Background: Recent innovations in the field of liver transplantation have led to a wealth of new treatment regimes, with potential impact on the onset of de novo malignancies (DNM). The aim of this multicenter cohort study was to provide contemporary figures for the cumulative incidences of solid and hematological DNM after liver transplantation.
Methods: We designed a retrospective cohort study including patients undergoing LT between 2000 and 2015 in three Italian transplant centers.
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Clin Transplant
February 2018
Infectious and Liver Diseases, Lazzaro Spallanzani National Infectious Disease Institute, Rome, Italy.
Background: In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this "real-life" study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV).
Methods: All HCV LT recipients with severe fibrosis in 15 Italian transplant centers were treated with DCV+SOF±RBV for 24 weeks; sustained virological response was assessed at 12 weeks post-treatment (SVR12).